Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes

Prandial Oriented NovoMix 30® - the Physiological Insulin Therapy of Diabetes Type 2

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01536652

Acronym

ProMix

Enrollment

4994

Registered

2012-02-22

Start date

2006-01-31

Completion date

2006-11-30

Last updated

2016-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Europe. The aim of this observational study is to document the glycaemic parameters, adverse events, including drug reactions, as well as hypoglycaemic episodes, in patients that switched from insulin glargine combined with oral antidiabetic drugs (OADs) to biphasic insulin aspart 30 (NovoMix® 30) combined with OADs, when applicable.

Interventions

DRUGbiphasic insulin aspart 30

Prescription at the discretion of the treating physician

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Subjects with diabetes mellitus type 2

Design outcomes

Primary

Measure	Time frame
HbA1c (glycosylated haemoglobin)	—

Secondary

Measure	Time frame
Body weight	—
Preprandial and postprandial blood glucose values (self measured)	—
Insulin dosage	—
Incidence of (serious) adverse drug reactions	—
Incidence of hypoglycaemic episodes	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026